"10.1371_journal.pone.0093933","plos one","2014-04-03T00:00:00Z","Emily Eva Holmes; Maria Jung; Sebastian Meller; Annette Leisse; Verena Sailer; Julie Zech; Martina Mengdehl; Leif-Alexander Garbe; Barbara Uhl; Glen Kristiansen; Dimo Dietrich","University Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany; Berlin Institute of Technology (TU Berlin), Biotechnology, Berlin, Germany","Conceived and designed the experiments: EEH DD MJ. Performed the experiments: EEH MJ SM BU. Analyzed the data: EEH BU SM DD MJ VS. Contributed reagents/materials/analysis tools: AL LG JZ MM. Wrote the paper: DD MJ EEH GK.","Dimo Dietrich has been an employee and is stockholder of Epigenomics AG, a company that aims to commercialize the DNA methylation biomarkers SEPT9 and SHOX2. Dimo Dietrich is co-inventor and owns patents on methylation biomarkers and related technologies. Patents: A Method for Amplification of Nucleic Acids (WO2006113770), A Method for the Carry-over Protection in DNA Amplification Systems Targeting Methylation Analysis Achieved by a Modified Pre-treatment of nucleic Acids (WO2006040187). These patents are commercially exploited by Epigenomics AG. Dimo Dietrich receives inventors compensation from Epigenomics AG. Dimo Dietrich is consultant of AJ Innuscreen GmbH (Berlin, Germany) and receives royalties from product sales. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","04","Emily Eva Holmes","EEH",11,TRUE,3,4,6,4,TRUE,TRUE,FALSE,0,NA,FALSE
